Research programme: dry eye disease therapeutics - Eyenovia/SGN Nanopharma
Alternative Names: Dry eye disease therapeutics - Eyenovia/SGN NanopharmaLatest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Eyenovia
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry eyes